ES2139957T3 - Metodo para la determinacion del estado pretrombotico. - Google Patents

Metodo para la determinacion del estado pretrombotico.

Info

Publication number
ES2139957T3
ES2139957T3 ES95942622T ES95942622T ES2139957T3 ES 2139957 T3 ES2139957 T3 ES 2139957T3 ES 95942622 T ES95942622 T ES 95942622T ES 95942622 T ES95942622 T ES 95942622T ES 2139957 T3 ES2139957 T3 ES 2139957T3
Authority
ES
Spain
Prior art keywords
determination
prethrombotic state
prethrombotic
state
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95942622T
Other languages
English (en)
Inventor
Jean-Marie Freyssinet
Benedicte Antoni
Frederic Donie
Helmut Lill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2139957T3 publication Critical patent/ES2139957T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON UN METODO PARA LA DETERMINACION DEL ESTADO PRETROMBOTICO DE UN INDIVIDUO. MAS CONCRETAMENTE, LA PRESENTE INVENCION SE RELACIONA CON UN METODO PARA LA DETERMINACION DE LAS MICROPARTICULAS DE CIRCULACION Y/O CELULAS PROCOAGULANTES ESTIMULADAS, CON UN METODO PARA LA DETERMINACION DE UNA CATEGORIA ESPECIAL DE MICROPARTICULAS DE CIRCULACION Y/O PROCOAGULANTES ESTIMULADOS ASI COMO CON UN METODO PARA LA DETERMINACION DE ANTICUERPOS DE UNION DE FOSFOLIPIDOS QUE ESTAN RELACIONADOS CON ENFERMEDADES CON UN RIESGO TROMBOTICO ALTO O CON ENFERMEDADES ASOCIADAS CON APOPTOSIS.
ES95942622T 1994-07-23 1995-07-19 Metodo para la determinacion del estado pretrombotico. Expired - Lifetime ES2139957T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94111514 1994-07-23

Publications (1)

Publication Number Publication Date
ES2139957T3 true ES2139957T3 (es) 2000-02-16

Family

ID=8216140

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95942622T Expired - Lifetime ES2139957T3 (es) 1994-07-23 1995-07-19 Metodo para la determinacion del estado pretrombotico.

Country Status (7)

Country Link
US (1) US7005271B1 (es)
EP (1) EP0772778B1 (es)
JP (1) JP3574659B2 (es)
AT (1) ATE186121T1 (es)
DE (1) DE69513027T2 (es)
ES (1) ES2139957T3 (es)
WO (1) WO1996003655A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002992A1 (en) 1997-07-11 1999-01-21 The Mount Sinai School Of Medicine Of The City University Of New York Assays for diagnosis of thrombophilic disease
US7687272B1 (en) 1998-01-12 2010-03-30 Henry Buchwald Method and apparatus for determining blood oxygen transport
AU1218900A (en) * 1998-10-23 2000-05-15 Accumetrics, Inc. Method for determining platelet count
US6806091B1 (en) 1999-01-12 2004-10-19 Henry Buchwald Method and apparatus for determining blood oxygen transport
DE60138111D1 (de) * 2000-07-21 2009-05-07 Chemo Sero Therapeut Res Inst Verfahren zur reinigung eines kalziumionen-bindenden proteins
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
WO2002067857A2 (en) 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US6746872B2 (en) 2002-01-16 2004-06-08 Lifescan, Inc. Control compositions and methods of use for coagulation tests
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
ATE536889T1 (de) 2003-07-08 2011-12-15 Accumetrics Inc Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten
WO2007086069A1 (en) * 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
EP2696203A3 (en) 2007-08-16 2014-05-28 The Royal Institution for the Advancement of Learning/McGill University Tumor cell-derived microvesicles
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US9012168B2 (en) 2010-07-29 2015-04-21 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
EP2809796A4 (en) * 2012-02-01 2016-08-17 Shire Human Genetic Therapies TESTS FOR THE DETECTION OF GLYCOSAMINOGLYCANES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668638A (en) 1983-03-24 1987-05-26 The Liposome Company, Inc. Liposome composition for lupus assay
FR2621128B1 (fr) 1987-09-30 1994-05-06 Sanofi Trousse et methode de dosage immunometrique applicables a des cellules entieres
US5340719A (en) 1990-11-23 1994-08-23 Corporation Coulter Method and apparatus for optically screening microscopic cells
US5266462A (en) * 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
CA2072548A1 (en) 1992-06-26 1993-12-27 Michael W. Stewart Methods for determining antiphospholipid antibodies
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
US5472852A (en) * 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients

Also Published As

Publication number Publication date
JPH10503023A (ja) 1998-03-17
US7005271B1 (en) 2006-02-28
JP3574659B2 (ja) 2004-10-06
EP0772778A1 (en) 1997-05-14
WO1996003655A1 (en) 1996-02-08
ATE186121T1 (de) 1999-11-15
DE69513027T2 (de) 2000-03-16
EP0772778B1 (en) 1999-10-27
DE69513027D1 (de) 1999-12-02

Similar Documents

Publication Publication Date Title
BG46598A3 (bg) Метод за получаване на алфа-хетероциклично заместени толунитрили
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ATE186121T1 (de) Verfahren zur bestimmung des präthrombotischen status
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
DK0986382T3 (da) RAF-kinasehæmmere
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
TR199801361T2 (xx) Yeni ikameli imidazol bile�imleri.
EA199800667A1 (ru) Новые фенантридины
TR199801360T2 (xx) Yeni ikameli imidazol bile�imleri.
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
TR200000662T2 (tr) Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.
TR199900505T2 (es)
BG40815A3 (bg) Метод за получаване на пептиди
NO885836L (no) Kvantitativ metode for bestemmelse av 1,4-dihydronikotinamid-adenin-dinukleotid i opploesning.
ATE343630T1 (de) Unsterbliche vogelzellen
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
BR6401363U (pt) Valvula de descarga rapida,para emprego em estimuladores de circulacao de sangue
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
IT8420757A0 (it) Metodi e composizioni di fumigazione.
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
PE20399A1 (es) Muteina ob
IT8447751A0 (it) Composizione contenente polisaccaride per legare proteine specifiche, metodo per ottenerla e procedimento nonche' corredo di saggio che la impiegano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 772778

Country of ref document: ES